Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
| Autor: | ROSTI G, MARTINELLI G, BASSI S, AMABILE M, TRABACCHI E, GIANNINI B, CILLONI D, IZZO, BARBARA, DE VIVO A, TESTONI N, CAMBRIN GR, BONIFAZI F, SOVERINI S, LUATTI S, GOTTARDI E, ALBERTI D, PANE, FABRIZIO, SALVATORE F, SAGLIO G, BACCARANI M, STUDY COMMITTEE, ITALIAN COOPERATIVE STUDY GROUP FOR CHRONIC MYELOID LEUKEMIA, WRITING COMMITTEE, ITALIAN COOPERATIVE STUDY GROUP FOR CHRONIC MYELOID L.E.U.K.E.M.I.A. |
|---|---|
| Přispěvatelé: | ROSTI G., MARTINELLI G., BASSI S., AMABILE M., TRABACCHI E., GIANNINI B., CILLONI D., IZZO B., DE VIVO A., TESTONI N., CAMBRIN G. R., BONIFAZI F., SOVERINI S., LUATTI S., GOTTARDI E., ALBERTI D., PANE F., SALVATORE F., SAGLIO G., BACCARANI M., STUDY COMMITTEE, ITALIAN COOPERATIVE STUDY GROUP ON CHRONIC MYELOID LEUKEMIA, WRITING COMMITTEE, Rosti, G, Martinelli, G, Bassi, S, Amabile, M, Trabacchi, E, Giannini, B, Cilloni, D, Izzo, Barbara, DE VIVO, A, Testoni, N, Cambrin, Gr, Bonifazi, F, Soverini, S, Luatti, S, Gottardi, E, Alberti, D, Pane, Fabrizio, Salvatore, F, Saglio, G, Baccarani, M, Study, Committee, ITALIAN COOPERATIVE STUDY GROUP FOR CHRONIC MYELOID, Leukemia, Writing, Committee, ITALIAN COOPERATIVE STUDY GROUP FOR CHRONIC MYELOID, L. E. U. K. E. M. I. A. |
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
POLYMERASE-CHAIN-REACTION
Immunology IMATINIB MESYLATE Alpha interferon Antineoplastic Agents Bone Marrow Cells INTERFERON-ALPHA THERAPY Genes abl PHILADELPHIA-CHROMOSOME Biochemistry Piperazines Myelogenous Recurrence Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Humans Medicine CHRONIC MYELOGENOUS LEUKEMIA TYROSINE KINASE INHIBITOR MINIMAL-RESIDUAL-DISEASE BONE-MARROW-TRANSPLANTATION FUSION GENE TRANSCRIPTS ABL-POSITIVE CELLS BCR-ABL Philadelphia-positive MOLECULAR RESPONSE CHRONIC MYELOID LEUKEMIA ABL business.industry breakpoint cluster region Myeloid leukemia Imatinib Cell Biology Hematology medicine.disease Leukemia Pyrimidines Treatment Outcome Imatinib mesylate Benzamides Cancer research beta 2-Microglobulin business Follow-Up Studies medicine.drug |
| Popis: | Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic remissions in patients with chronic myeloid leukemia (CML). In these patients measuring response by molecular techniques is clearly required. We determined the cytogenetic and molecular response (CgR, MR) to imatinib in 191 patients with late chronic-phase Philadelphia-positive (Ph+) CML, previously treated with interferon α. MR was assessed with real-time quantitative (TaqMan) reverse transcription–polymerase chain reaction and was expressed as the ratio between BCR/ABL and β2-microglobulin × 100, the lowest level of detectability of the method being 0.00001. A complete CgR (CCgR) was achieved in 85 (44%) of 191 patients and was maintained for 2 years in 67 (79%) of 85 patients. A reduction of the transcript level of more than 2 logs was achieved in all but 9 patients with CCgR versus none of 23 with partial CgR. In the CCgRs the median value of the MR was 0.0008 after 12 months and 0.0001 after 24 months, with the transcript level undetectable in 22 cases. We conclude that in CCgRs the degree of MR may vary from 2 to more than 4 logs, and that there is a progressive decrease of transcript level by time. Only 1 of 22 negative cases has had a relapse as yet. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|